Norio Nakatsuji/X
Jun 20, 2026, 07:09
Norio Nakatsuji: LRP5 Inhibition Shows Promise for Safer Blood-Thinning Strategies
Norio Nakatsuji, Professor Emeritus at Kyoto University, Director General at Nakatsuji Foresight Foundation, Chief Advisor at Stem Cell and Device Lab, Inc. Bluesky, shared on X:
”LRP5 Inhibition Shows Promise for Safer Blood-Thinning Strategies
‘LRP5 inhibition reduced platelet activation and thrombosis with lower bleeding impact than current drugs.”’
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 20, 2026, 07:02Sex Hormone Influences on Venous Thrombosis in Episode 32 of CLOT Conversations – Thrombosis Canada
-
Jun 20, 2026, 06:57Shayan Mohammadmoradi: Excited to Share New Insights Into Platelet α-Granule Integrity and Aortic Aneurysms at ISTH 2026
-
Jun 20, 2026, 06:46The Inspiring Journey of Padma Shri Dr. Suresh Hanagavadi – Karnataka Hemophilia Society Davanagere
-
Jun 20, 2026, 06:39Rethinking Physical Activity in the Era of Modern Hemophilia Care – Hematology Advisor
-
Jun 20, 2026, 06:29Bernard Slater Jr.: Hope on the Horizon as Hemophilia B Treatment Continues to Evolve
-
Jun 20, 2026, 04:46Mayka Sanchez: Advancing Rare Anemia Research at the EIC 2026
-
Jun 20, 2026, 04:25Holly John: The Fight for Equitable Sickle Cell Care Is a Fight for Freedom
-
Jun 20, 2026, 03:59Alejandro González Veliz: Why Recovery After Myocardial Infarction Does Not End at Discharge
-
Jun 20, 2026, 02:21Octavio Marques Pontes-Neto: Proud to Receive an Award as an Advanced Stroke Center by the WSO at Global Stroke Alliance 2026